Characteristics and Research Progress of SARS-CoV-2 Vaccine Developed by Different Technical Routes

QIAN Manyun; LI Yafeng

doi:10.12405/j.issn.2097-1486.2022.01.007

您当前的位置：

首页 >

文章列表页 >

Characteristics and Research Progress of SARS-CoV-2 Vaccine Developed by Different Technical Routes

更新时间：2024-11-01

- Characteristics and Research Progress of SARS-CoV-2 Vaccine Developed by Different Technical Routes
- Emerging Science and Technology Vol. 1, Issue 1, Pages: 71-79(2022)
- 作者机构：
  
  1.山西医科大学　基础医学院生物化学与分子生物学教研室，山西　太原　030001
  2.山西医科大学　第五临床医学院（山西省人民医院）中心实验室，山西　太原　030012
  3.肾脏病山西省重点实验室，山西　太原　030012
  4.山西医科大学　微生态研究院，山西　太原　030001
- 作者简介：
- 基金信息：
- DOI：10.12405/j.issn.2097-1486.2022.01.007
  CLC： R392
- Published：2022-09，
  
  Received：13 April 2022，
  
  Revised：11 May 2022，
- 稿件说明：
移动端阅览
钱曼云,李亚峰.不同技术路线研发新型冠状病毒疫苗的特性和研究进展[J].新兴科学和技术趋势,2022,1(1):71-79.

QIAN Manyun, LI Yafeng. Characteristics and Research Progress of SARS-CoV-2 Vaccine Developed by Different Technical Routes. [J]. Emerging Science and Technology, 2022,1(1):71-79.
钱曼云,李亚峰.不同技术路线研发新型冠状病毒疫苗的特性和研究进展[J].新兴科学和技术趋势,2022,1(1):71-79. DOI： 10.12405/j.issn.2097-1486.2022.01.007.

QIAN Manyun, LI Yafeng. Characteristics and Research Progress of SARS-CoV-2 Vaccine Developed by Different Technical Routes. [J]. Emerging Science and Technology, 2022,1(1):71-79. DOI： 10.12405/j.issn.2097-1486.2022.01.007.

摘要

席卷全球的新型冠状病毒肺炎（corona virus disease 2019，COVID-19，以下简称新冠肺炎）疫情给全人类的生命健康安全带来巨大威胁，传播速度快、感染率高是新冠肺炎的典型特点，据历史经验，及时接种疫苗可以有效阻止疫情传播。在疫情爆发后，积极有效地启动研发新型冠状病毒（SARS-CoV-2）疫苗成为全球科学家及科研机构的共同目标。在疫苗研发和设计的过程中，一些经获批使用的SARS-CoV-2疫苗具有较好的安全性和免疫原性，其临床试验已证实了具有良好的保护效力。根据SARS-CoV-2疫苗研发的技术路线不同，疫苗主要包括灭活疫苗（inactivated virus vaccine）、重组蛋白疫苗（recombinant protein vaccine）、病毒载体疫苗（viral vector-based vaccine）和核酸疫苗（nucleic acid vaccine）等。本文对各类疫苗优缺点和研制进展进行综述，阐述SARS-CoV-2疫苗所面临的一些问题，为疫苗后续的改进提供有益借鉴。

Abstract

The global epidemic of coronavirus coronavirus 2019 (COVID-19) has brought great threat to the life and the health of human beings. The rapid spread and high infection rate are typical characteristics of new coronavirus pneumonia; timely vaccination can effectively prevent the spread of the epidemic. After the outbreak of the epidemic

the active and effective launch of research and development of SARS-CoV-2 vaccine has become a common goal of scientists and research institutions around the world. In the course of vaccine development and design

some approved SARS-CoV-2 vaccines have good safety and immunogenicity

and their clinical trials have proved their protective efficacy. According to the different technical route of development of SARS-CoV-2 vaccine

vaccines mainly include inactivated vaccine

recombinant protein vaccine

viral vector-based vaccine and nucleic acid vaccine. In this paper

the advantages and disadvantages of all kinds of vaccines and the development of SARS-CoV-2 vaccine were reviewed

and some problems of SARS-CoV-2 vaccine were discussed.

关键词

新型冠状病毒新型冠状病毒肺炎疫苗

Keywords

SARS-CoV-2COVID-19vaccine

references

陈一晖, 李武.新冠肺炎(Covid-19)的临床症状、临床分类与诊断[J].基因组学与应用生物学, 2020, 39(08): 3904-3907. doi: 10.13417/j.gab.039.003904http://doi.org/10.13417/j.gab.039.003904.

IZDA V, JEFFRIES MA, SAWALHA AH. COVID-19: A review of therapeutic strategies and vaccine candidates[J]. Clin Immunol, 2021, 222: 108634. doi: 10.1016/j.clim.2020.108634http://doi.org/10.1016/j.clim.2020.108634.

KEEHNER J, HORTON LE, PFEFFER MA, et al. SARS-CoV-2Infection after Vaccination in Health Care Workers in California[J]. N Engl J Med, 2021, 384(18): 1774-1775. doi: 10.1056/NEJMc2101927http://doi.org/10.1056/NEJMc2101927.

LEE HJ, WOO Y, HAHN TW, et al. Formation and Maturation of the Phagosome: A Key Mechanism in Innate Immunity against Intracellular Bacterial Infection[J]. Microorganisms, 2020, 8(9): 1298. doi: 10.3390/microorganisms8091298http://doi.org/10.3390/microorganisms8091298.

ROSALES C, URIBE-QUEROL E. Phagocytosis: A Fundamental Process in Immunity[J]. Biomed Res Int, 2017, 2017: 9042851. doi: 10.1155/2017/9042851http://doi.org/10.1155/2017/9042851.

ZABEL F, FETTELSCHOSS A, VOGEL M, et al. Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation[J]. Immunology, 2017, 150(3): 329-342. doi: 10.1111/imm.12688http://doi.org/10.1111/imm.12688.

杨玉莹, 左代英.新型冠状病毒疫苗研发进展[J].沈阳药科大学学报, 2021, 38(07): 762-769. doi: 10.14066/j.cnki.cn21-1349/r.2021.0143http://doi.org/10.14066/j.cnki.cn21-1349/r.2021.0143.

ALTURKI SO, ALTURKI SO, CONNORS J, et al. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development[J]. Front Immunol, 2020, 11: 1880. doi: 10.3389/fimmu.2020.01880http://doi.org/10.3389/fimmu.2020.01880.

LIU X, LIU C, LIU G, et al. COVID-19: Progress in diagnostics, therapy and vaccination[J]. Theranostics, 2020, 10(17): 7821-7835. doi: 10.7150/thno.47987http://doi.org/10.7150/thno.47987.

WON JH, LEE H. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic[J]. Int J Mol Sci, 2020, 21(24): 9775. doi: 10.3390/ijms21249775http://doi.org/10.3390/ijms21249775.

TUMBAN E. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval[J]. Viruses, 2020, 13(1): 54. doi: 10.3390/v13010054http://doi.org/10.3390/v13010054.

TREGONING JS, BROWN ES, CHEESEMAN HM, et al. Vaccines for COVID-19[J]. Clin Exp Immunol, 2020, 202(2): 162-192. doi: 10.1111/cei.13517http://doi.org/10.1111/cei.13517.

付钰倩, 芦增增, 黄妙惠.新型冠状病毒肺炎免疫反应与疫苗开发的研究进展[J].福建轻纺, 2021(06): 2-7+12. doi: 10.3969/j.issn.1007-550X.2021.06.001http://doi.org/10.3969/j.issn.1007-550X.2021.06.001.

白仲虎, 李昕然, 王荣斌, 等.哺乳动物细胞生产人用灭活疫苗相关技术进展[J].中国细胞生物学学报, 2019, 41(10): 1986-1993. doi: 10.11844/cjcb.2019.10.0016http://doi.org/10.11844/cjcb.2019.10.0016.

金翔, 俞庆龄, 张璐楠, 等.针对新型冠状病毒的DNA疫苗研究进展[J].中国新药杂志, 2020, 29(21): 2425-2433. doi: 10.3969/j.issn.1003-3734.2020.21.006http://doi.org/10.3969/j.issn.1003-3734.2020.21.006.

MULLIGAN MJ. An Inactivated Virus Candidate Vaccine to Prevent COVID-19[J]. JAMA, 2020, 324(10): 943-945. doi: 10.1001/jama.2020.15539http://doi.org/10.1001/jama.2020.15539.

桓瑜, 毕玉海.2019新型冠状病毒疫苗研究进展及展望[J].中国科学：生命科学, 2022, 52(02): 237-248. doi: 10.1360/SSV-2021-0082http://doi.org/10.1360/SSV-2021-0082.

黄苏玥, 沈银忠.新型冠状病毒疫苗的研发进展[J].上海医药, 2021, 42(17): 16-21. doi: 10.3969/j.issn.1006-1533.2021.17.005http://doi.org/10.3969/j.issn.1006-1533.2021.17.005.

HOLMES KV. SARS coronavirus: a new challenge for prevention and therapy[J]. J Clin Invest, 2003, 111(11): 1605-9. doi: 10.1172/JCI18819http://doi.org/10.1172/JCI18819.

DENG Y, LAN J, BAO L, et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus[J]. Emerg Microbes Infect, 2018, 7(1): 60. doi: 10.1038/s41426-018-0056-7http://doi.org/10.1038/s41426-018-0056-7.

WU Z, HU Y, XU M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial[J]. Lancet Infect Dis, 2021, 21(6): 803-812. doi: 10.1016/S1473-3099(20)30987-7http://doi.org/10.1016/S1473-3099(20)30987-7.

XIA S, ZHANG Y, WANG Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebocontrolled, phase 1/2 trial[J]. Lancet Infect Dis, 2021, 21(1): 39-51. doi: 10.1016/S1473-3099(20)30831-8http://doi.org/10.1016/S1473-3099(20)30831-8.

XIA S, ZHANG Y, WANG Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial[J]. Lancet Infect Dis, 2022, 22(2): 196-208. doi: 10.1016/S1473-3099(21)00462-Xhttp://doi.org/10.1016/S1473-3099(21)00462-X.

VÁLYI-NAGY I, MATULA Z, GÖNCZI M, et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans[J]. Geroscience, 2021, 43(5): 2321-2331. doi: 10.1007/s11357-021-00471-6http://doi.org/10.1007/s11357-021-00471-6.

史长城, 李晴宇, 朱洁瑾, 等.新型冠状病毒肺炎疫苗的临床试验研究进展[J].中国现代应用药学, 2021, 38(21): 2748-2753. doi: 10.13748/j.cnki.issn1007-7693.2021.21.019http://doi.org/10.13748/j.cnki.issn1007-7693.2021.21.019.

ELLA R, VADREVU KM, JOGDAND H, et al. Safety and immunogenicity of an inactivated SARSCoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial[J]. Lancet Infect Dis, 2021, 21(5): 637-646. doi: 10.1016/S1473-3099(21)00070-0http://doi.org/10.1016/S1473-3099(21)00070-0.

ELLA R, REDDY S, JOGDAND H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a doubleblind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial[J]. Lancet Infect Dis, 2021, 21(7): 950-961. doi: 10.1016/S1473-3099(21)00070-0http://doi.org/10.1016/S1473-3099(21)00070-0.

ELLA R, REDDY S, BLACKWELDER W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial[J]. Lancet, 2021, 398(10317): 2173-2184. doi: 10.1016/S0140-6736(21)02000-6http://doi.org/10.1016/S0140-6736(21)02000-6.

KARPIŃSKI TM, OŻAROWSKI M, SEREMAKMROZIKIEWICZ A, et al. The 2020 race towards SARS-CoV-2 specific vaccines[J]. Theranostics, 2021, 11(4): 1690-1702. doi: 10.7150/thno.5369http://doi.org/10.7150/thno.5369.

LI YD, CHI WY, SU JH, et al. Coronavirus vaccine development: from SARS and MERS to COVID-19[J]. J Biomed Sci, 2020, 27(1): 104. doi: 10.1186/s12929-020-00695-2http://doi.org/10.1186/s12929-020-00695-2.

廖盼, 肖义军.新冠病毒疫苗研发策略与进展概述[J].生物学教学, 2021, 46(05): 8-10. doi: 10.3969/j.issn.1004-7549.2021.05.003http://doi.org/10.3969/j.issn.1004-7549.2021.05.003.

方朝东, 张玉辉, 吴浩飞, 等.新型冠状病毒肺炎疫苗研究进展概述[J].中国药师, 2020, 23(09): 1826-1830. doi: 10.3969/j.issn.1008-049X.2020.09.037http://doi.org/10.3969/j.issn.1008-049X.2020.09.037.

ROLDÃO A, MELLADO MC, CASTILHO LR, et al. Virus-like particles in vaccine development[J]. Expert Rev Vaccines, 2010, 9(10): 1149-1176. doi: 10.1586/erv.10.115http://doi.org/10.1586/erv.10.115.

CAO Y, ZHU X, HOSSEN MN, et al. Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant[J]. Nat Commun, 2018, 9(1): 3695. doi: 10.1038/s41467-018-06151-yhttp://doi.org/10.1038/s41467-018-06151-y.

KAUR SP, GUPTA V. COVID-19 Vaccine: A comprehensive status report[J]. Virus Res, 2020, 288: 198114. doi: 10.1016/j.virusres.2020.198114http://doi.org/10.1016/j.virusres.2020.198114.

WANG J, PENG Y, XU H, et al. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation[J]. AAPS PharmSciTech, 2020, 21(6): 225. doi: 10.1208/s12249-020-01744-7http://doi.org/10.1208/s12249-020-01744-7.

BHAT EA, KHAN J, SAJJAD N, et al. SARSCoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis-An updated review[J]. Int Immunopharmacol, 2021, 95: 107493. doi: 10.1016/j.intimp.2021.107493http://doi.org/10.1016/j.intimp.2021.107493.

KEECH C, ALBERT G, CHO I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine[J]. N Engl J Med, 2020, 383(24): 2320-2332. doi: 10.1056/NEJMoa2026920http://doi.org/10.1056/NEJMoa2026920.

李晓瑞, 李兴航, 严汉池.新型冠状病毒疫苗的研发现状及展望[J].中国生物制品学杂志, 2021, 34(05): 602-606. doi: 10.13200/j.cnki.cjb.003343http://doi.org/10.13200/j.cnki.cjb.003343.

HUMPHREYS IR, SEBASTIAN S. Novel viral vectors in infectious diseases[J]. Immunology, 2018, 153(1): 1-9. doi: 10.1111/imm.12829http://doi.org/10.1111/imm.12829.

BOS R, RUTTEN L, VAN DER LUBBE JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses[J]. NPJ Vaccines, 2020, 5: 91. doi: 10.1038/s41541-020-00243-xhttp://doi.org/10.1038/s41541-020-00243-x.

LOGUNOV DY, DOLZHIKOVA IV, ZUBKOVA OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, nonrandomised phase 1/2 studies from Russia[J]. Lancet, 2020, 396(10255): 887-897. doi: 10.1016/S0140-6736(20)31866-3http://doi.org/10.1016/S0140-6736(20)31866-3.

成传刚, 慕婷, 袁军, 等.重组病毒载体疫苗研究进展[J].中国病毒病杂志, 2018, 8(04): 318-328. doi: 10.16505/j.2095-0136.2018.0024http://doi.org/10.16505/j.2095-0136.2018.0024.

ZHU FC, LI YH, GUAN XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial[J]. Lancet, 2020, 395(10240): 1845-1854. doi: 10.1016/S0140-6736(20)31208-3http://doi.org/10.1016/S0140-6736(20)31208-3.

HEININGER U. Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19[J]. N Engl J Med, 2021, 385(3): 288. doi: 10.1056/NEJMc2107809http://doi.org/10.1056/NEJMc2107809.

SHAY DK, GEE J, SU JR, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine-United States, March-April 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(18): 680-684. doi: 10.15585/mmwr.mm7018e2http://doi.org/10.15585/mmwr.mm7018e2.

VOYSEY M, CLEMENS SAC, MADHI SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK[J]. Lancet, 2021, 397(10269): 99-111. doi: 10.1016/S0140-6736(20)32661-1http://doi.org/10.1016/S0140-6736(20)32661-1.

GREINACHER A, THIELE T, WARKENTIN TE, et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination[J]. N Engl J Med, 2021, 384(22): 2092-2101. doi: 10.1056/NEJMoa2104840http://doi.org/10.1056/NEJMoa2104840.

MCCRAE KR. Thrombotic thrombocytopenia due to SARS-CoV-2 vaccination[J]. Cleve Clin JMed, 2021. doi: 10.3949/ccjm.88a.ccc078http://doi.org/10.3949/ccjm.88a.ccc078.

WISE J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots[J]. BMJ, 2021, 372: n699. doi: 10.1136/bmj.n699http://doi.org/10.1136/bmj.n699.

KUTZLER MA, WEINER DB. DNA vaccines: ready for prime time[J]. Nat Rev Genet, 2008, 9(10): 776-88. doi: 10.1038/nrg2432http://doi.org/10.1038/nrg2432.

PARDI N, HOGAN MJ, PORTER FW, et al. mRNA vaccines-a new era in vaccinology[J]. Nat Rev Drug Discov, 2018, 17(4): 261-279. doi: 10.1038/nrd.2017.243http://doi.org/10.1038/nrd.2017.243.

赵琪, 安静, 陈辉.登革病毒DNA疫苗的研究进展[J].军事医学, 2016, 40(11): 923-926. doi: 10.7644/j.issn.1674-9960.2016.11.017http://doi.org/10.7644/j.issn.1674-9960.2016.11.017.

于琨, 安丽平, 王伟, 等.流感疫苗的研究进展[J].现代预防医学, 2017, 44(14): 2644-2646+2650. doi: CNKI: SUN: XDYF.0.2017-14-037http://doi.org/CNKI: SUN: XDYF.0.2017-14-037.

SUSCHAK JJ, WILLIAMS JA, SCHMALJOHN CS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity[J]. Hum Vaccin Immunother, 2017, 13(12): 2837-2848. doi: 10.1080/21645515.2017.1330236http://doi.org/10.1080/21645515.2017.1330236.

MASCOLA JR, FAUCI AS. Novel vaccine technologies for the 21st century[J]. Nat Rev Immunol, 2020, 20(2): 87-88. doi: 10.1038/s41577-019-0243-3http://doi.org/10.1038/s41577-019-0243-3.

QIAN C, LIU X, XU Q, et al. Recent Progress on the Versatility of Virus-Like Particles[J]. Vaccines(Basel), 2020, 8(1): 139. doi: 10.3390/vaccines8010139http://doi.org/10.3390/vaccines8010139.

葛华, 蒋丽勇, 刘术, 等. COVID-19 mRNA疫苗关键技术与产品进展分析[J].军事医学, 2020, 44(04): 264-268. doi: 10.7644/j.issn.1674-9960.2020.04.005http://doi.org/10.7644/j.issn.1674-9960.2020.04.005.

MCIVOR RS. Therapeutic delivery of mRNA: the medium is the message[J]. Mol Ther, 2011, 19(5): 822-823. doi: 10.1038/mt.2011.67http://doi.org/10.1038/mt.2011.67.

MIAO L, LI L, HUANG Y, et al. Delivery of mRNA vaccines with heterocyclic lipids increases antitumor efficacy by STING-mediated immune cell activation[J]. Nat Biotechnol, 2019, 37(10): 1174-1185. doi: 10.1038/s41587-019-0247-3http://doi.org/10.1038/s41587-019-0247-3.

PASTOR F, BERRAONDO P, ETXEBERRIA I, et al. An RNA toolbox for cancer immunotherapy[J]. Nat Rev Drug Discov, 2018, 17(10): 751-767. doi: 10.1038/nrd.2018.132http://doi.org/10.1038/nrd.2018.132.

KLIMEK L, JUTEL M, AKDIS CA, et al. ARIAEAACI statement on severe allergic reactions to COVID-19 vaccines-An EAACI-ARIA Position Paper[J]. Allergy, 2021, 76(6): 1624-1628. doi: 10.1111/all.14726http://doi.org/10.1111/all.14726.

POLACK FP, THOMAS SJ, KITCHIN N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine[J]. N Engl J Med, 2020, 383(27): 2603-2615. doi: 10.1056/NEJMc2036242http://doi.org/10.1056/NEJMc2036242.

OLIVER SE, GARGANO JW, MARIN M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine-United States, December 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(50): 1922-1924. doi: 10.15585/mmwr.mm6950e2http://doi.org/10.15585/mmwr.mm6950e2.

WALSH EE, JRFRENCK RW, FALSEY AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates[J]. N Engl J Med, 2020, 383(25): 2439-2450. doi: 10.1056/NEJ-Moa2027906http://doi.org/10.1056/NEJ-Moa2027906.

BADEN LR, EL SAHLY HM, ESSINK B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine[J]. N Engl J Med, 2021 Feb 4, 384(5): 403-416. doi: 10.1056/NEJMoa2035389http://doi.org/10.1056/NEJMoa2035389.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research status and prospect of tuberculosis vaccine

Related Author

ZHANG Yongmin

LÜ Zhimin

LIU Hongyu

Related Institution

Research Center for Glycochemistry of Characteristic Medicinal Resources， Department of Chemistry and Chemical Engineering， Inner Mongolia University

⁰